NASDAQ:PPD
Delisted
PPD, Inc. Stock News
$47.28
+0 (+0%)
At Close: May 27, 2022
PPD 连续第二年荣膺2021年度“大中华区最佳职场TM”称号
08:00pm, Monday, 06'th Dec 2021
北卡罗来纳州威明顿--(BUSINESS WIRE)--PPD, Inc.(纳斯达克代码:PPD)被卓越职场(®Great Place to Work®)评为“ 2021年度大中华区最佳职场™ ”(Best Workplaces i
PPD Named ‘Best Vaccine CRO of the Year' in Asia-Pacific
09:00am, Thursday, 02'nd Dec 2021
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD named “Best Vaccine CRO of the Year” at the APAC Vaccine Excellence Awards 2021 for its strong presence, extensive experience and quality delivery
PPD Named ‘Best Vaccine CRO of the Year’ in Asia-Pacific
09:00am, Thursday, 02'nd Dec 2021
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) was named “Best Vaccine CRO of the Year” at the Asia-Pacific Vaccine Excellence Awards 2021 for its strong presence, extensive experience
IFM Investors Pty Ltd Decreases Stock Position in PPD, Inc. (NASDAQ:PPD)
11:34am, Saturday, 27'th Nov 2021 Transcript Daily
IFM Investors Pty Ltd reduced its position in PPD, Inc. (NASDAQ:PPD) by 6.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,909 shares of the companys stock after selling 1,258 shares during the quarter. IFM Investors Pty Ltds holdings in PPD were worth []
Zacks Investment Research Lowers PPD (NASDAQ:PPD) to Sell
09:32am, Saturday, 27'th Nov 2021 Transcript Daily
Zacks Investment Research lowered shares of PPD (NASDAQ:PPD) from a hold rating to a sell rating in a research report sent to investors on Wednesday, Zacks.com reports. According to Zacks, PPD Inc. is a contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. It serves pharmaceutical, biotechnology, medical device, academic and []
The real world evidence solutions market is expected to witness market growth at a rate of 12.22% in the forecast period of 2021 to 2028 and is expected to reach USD 1,933.16 million by 2028. Data Bridge Market Research report
PPD Wins Multiple Awards at Clinical Researcher of the Year Competition
09:00am, Monday, 22'nd Nov 2021
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) earned numerous honors at the 2021 PharmaTimes Clinical Researcher of the Year-The Americas competition. Two PPD teams won gold, one team won
HighVista Strategies LLC Buys Coupang Inc, PPD Inc, Kansas City Southern, Sells Willis Towers ...
11:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: ACRS , EPIX , CRIS , BGNE , RCKT , MRTX , CPNG , PPD , KSU , CHNG , FIVN , ARNA , WLTW , MXIM , ALXN , WORK , SOGO , GRUB ,
PPD, Inc. (NASDAQ:PPD) Position Increased by Marshall Wace LLP
02:52pm, Sunday, 14'th Nov 2021 Transcript Daily
Marshall Wace LLP raised its holdings in shares of PPD, Inc. (NASDAQ:PPD) by 56.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 338,478 shares of the companys stock after buying an additional 121,878 shares during the period. Marshall Wace LLP owned about 0.10% of []
Charles Schwab Investment Management Inc. Boosts Stock Holdings in PPD, Inc. (NASDAQ:PPD)
10:34am, Sunday, 14'th Nov 2021 Transcript Daily
Charles Schwab Investment Management Inc. boosted its position in shares of PPD, Inc. (NASDAQ:PPD) by 13.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 346,896 shares of the companys stock after buying an additional 39,993 shares during the period. []
PPD, Inc. (PPD) CEO David Simmons on Q3 2021 Results - Earnings Call Transcript
11:49am, Thursday, 28'th Oct 2021
PPD, Inc. (PPD) CEO David Simmons on Q3 2021 Results - Earnings Call Transcript
PPD, Inc. (PPD) Tops Q3 Earnings and Revenue Estimates
08:14pm, Wednesday, 27'th Oct 2021
PPD, Inc. (PPD) delivered earnings and revenue surprises of 16.22% and 7.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
PPD Reports Third Quarter and Year-To-Date 2021 Results
04:10pm, Wednesday, 27'th Oct 2021
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021. Highli
PALO ALTO, Calif.--(BUSINESS WIRE)-- #biotech--Medable secured $304 million in Series D funding at $2.1 billion valuation to accelerate global adoption of digital and decentralized clinical trials.
PPD Named Clinical Research Company of the Year for Second Consecutive Year
09:00am, Tuesday, 19'th Oct 2021
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) was named “Clinical Research Company of the Year” at the 2021 PharmaTimes Clinical Researcher of the Year International competition in Lo